Case Studies

Challenge: A major European venture capital investor needed help to review the business plan and competitive positioning of a novel point-of-care diagnostics company. The company was developing a...

Alacrita's diagnostics consultants were tasked with developing an ex-US business development strategy and identifying sources of non-dilutive finance for a well-funded venture capital funded...

Alacrita Consulting's founders worked together for over 10 years at Onyvax, a London-based cancer immunotherapy company backed by SR One. We have conducted a number of consulting projects in the...

Alacrita’s antibody consultants were engaged to help a start-up company that had developed a suite of proprietary antibody technologies to identify accessible cell surface proteins for discovery of...

Technology Consulting: Novel Antibody Screening Technology Alacrita's antibody consultants were asked to help assess the market potential and develop a commercialization strategy for a novel antibody...

Biologics Consulting: Antibodies to Treat Bacterial Infections An established US biotech company with $bn sales was looking for a team of expert antibody consultants to help them understand the...

Alacrita's radiopharmaceuticals consultant has had a distinguished career in the nuclear medicine industry. For a recent radiopharmaceuticals strategy project for a major public/private investor in a...

Valuations For a biotech company engaged in licensing discussions with a number of major pharmaceutical companies, Alacrita developed rNPV valuations for each program. This 'theoretical' valuation...

Due diligence For a financial investor, Alacrita conducted an IP assessment on a late stage cell therapy investment opportunity. The assessment revealed that the US and EPO patents relied on just...

Challenge: A leading cancer research charity needed project management and drug development expertise to shepherd two preclinical programs into Phase I/II clinical trials. Alacrita was engaged to...

Target Assessment and intellectual property For a mid-cap pharmaceutical company seeking to establish a biologics pipeline through partnership with a mAb development boutique, Alacrita assessed the...

Background Alacrita`s client was nearing the completion of a pivotal Phase III with a novel antibody-based therapeutic. The product was designed to delay recurrence in cancer patients with minimum...